PL1863767T3 - Metabolity antagonistów NK-1 do leczenia wymiotów - Google Patents
Metabolity antagonistów NK-1 do leczenia wymiotówInfo
- Publication number
- PL1863767T3 PL1863767T3 PL06707550T PL06707550T PL1863767T3 PL 1863767 T3 PL1863767 T3 PL 1863767T3 PL 06707550 T PL06707550 T PL 06707550T PL 06707550 T PL06707550 T PL 06707550T PL 1863767 T3 PL1863767 T3 PL 1863767T3
- Authority
- PL
- Poland
- Prior art keywords
- emesis
- metabolites
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05102359 | 2005-03-23 | ||
EP06707550A EP1863767B1 (en) | 2005-03-23 | 2006-03-14 | Metabolites for nk-i antagonists for emesis |
PCT/EP2006/002313 WO2006099968A1 (en) | 2005-03-23 | 2006-03-14 | Metabolites for nk-i antagonists for emesis |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1863767T3 true PL1863767T3 (pl) | 2009-08-31 |
Family
ID=36587133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06707550T PL1863767T3 (pl) | 2005-03-23 | 2006-03-14 | Metabolity antagonistów NK-1 do leczenia wymiotów |
Country Status (22)
Country | Link |
---|---|
US (1) | US7211579B2 (pl) |
EP (1) | EP1863767B1 (pl) |
JP (1) | JP4768010B2 (pl) |
KR (1) | KR100903224B1 (pl) |
CN (1) | CN101146775B (pl) |
AR (1) | AR052949A1 (pl) |
AT (1) | ATE425144T1 (pl) |
AU (1) | AU2006226665B2 (pl) |
BR (1) | BRPI0609699A2 (pl) |
CA (1) | CA2602445C (pl) |
DE (1) | DE602006005624D1 (pl) |
DK (1) | DK1863767T3 (pl) |
ES (1) | ES2320590T3 (pl) |
IL (1) | IL185689A (pl) |
MX (1) | MX2007011489A (pl) |
NO (1) | NO20074622L (pl) |
PL (1) | PL1863767T3 (pl) |
PT (1) | PT1863767E (pl) |
RU (1) | RU2404969C2 (pl) |
TW (1) | TWI316056B (pl) |
WO (1) | WO2006099968A1 (pl) |
ZA (1) | ZA200708029B (pl) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007000198A (es) | 2004-07-06 | 2007-03-15 | Hoffmann La Roche | Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1. |
US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
US9403772B2 (en) | 2011-11-29 | 2016-08-02 | Helsinn Healthcare Sa | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
EP3067349B1 (en) | 2013-11-08 | 2018-02-28 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
WO2015171489A1 (en) * | 2014-05-05 | 2015-11-12 | Apicore Us Llc | Methods of making netupitant and intermediates thereof |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
CN112174881B (zh) * | 2019-07-04 | 2022-06-21 | 上海森辉医药有限公司 | 一种奈妥匹坦的衍生物及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4745123A (en) | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
ATE278687T1 (de) | 1993-12-29 | 2004-10-15 | Merck Sharp & Dohme | Substituierte morpholinderivate und ihre verwendung als therapeutische mittel |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
EP1035115B1 (en) * | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
DE60006340T2 (de) * | 1999-11-29 | 2004-09-09 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid |
AU2001263021A1 (en) * | 2000-05-10 | 2001-11-20 | Bristol-Myers Squibb Company | Alkylamine derivatives of dihydropyridine npy antagonists |
SI1303490T1 (sl) * | 2000-07-14 | 2008-10-31 | Hoffmann La Roche | N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
WO2005002577A1 (en) * | 2003-07-03 | 2005-01-13 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
-
2006
- 2006-03-14 AU AU2006226665A patent/AU2006226665B2/en not_active Ceased
- 2006-03-14 DE DE602006005624T patent/DE602006005624D1/de active Active
- 2006-03-14 BR BRPI0609699-9A patent/BRPI0609699A2/pt not_active IP Right Cessation
- 2006-03-14 AT AT06707550T patent/ATE425144T1/de active
- 2006-03-14 WO PCT/EP2006/002313 patent/WO2006099968A1/en active Application Filing
- 2006-03-14 CA CA2602445A patent/CA2602445C/en not_active Expired - Fee Related
- 2006-03-14 CN CN2006800094426A patent/CN101146775B/zh active Active
- 2006-03-14 PT PT06707550T patent/PT1863767E/pt unknown
- 2006-03-14 PL PL06707550T patent/PL1863767T3/pl unknown
- 2006-03-14 KR KR1020077021748A patent/KR100903224B1/ko active IP Right Grant
- 2006-03-14 RU RU2007134901/04A patent/RU2404969C2/ru not_active IP Right Cessation
- 2006-03-14 ES ES06707550T patent/ES2320590T3/es active Active
- 2006-03-14 JP JP2008502283A patent/JP4768010B2/ja not_active Expired - Fee Related
- 2006-03-14 MX MX2007011489A patent/MX2007011489A/es active IP Right Grant
- 2006-03-14 EP EP06707550A patent/EP1863767B1/en active Active
- 2006-03-14 DK DK06707550T patent/DK1863767T3/da active
- 2006-03-15 US US11/376,042 patent/US7211579B2/en active Active
- 2006-03-20 TW TW095109514A patent/TWI316056B/zh not_active IP Right Cessation
- 2006-03-21 AR ARP060101093A patent/AR052949A1/es unknown
-
2007
- 2007-09-03 IL IL185689A patent/IL185689A/en not_active IP Right Cessation
- 2007-09-12 NO NO20074622A patent/NO20074622L/no not_active Application Discontinuation
- 2007-09-18 ZA ZA200708029A patent/ZA200708029B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
TWI316056B (en) | 2009-10-21 |
JP2008534454A (ja) | 2008-08-28 |
IL185689A0 (en) | 2008-01-06 |
US20060217393A1 (en) | 2006-09-28 |
KR20070107146A (ko) | 2007-11-06 |
MX2007011489A (es) | 2007-10-11 |
CN101146775A (zh) | 2008-03-19 |
WO2006099968A1 (en) | 2006-09-28 |
AR052949A1 (es) | 2007-04-11 |
JP4768010B2 (ja) | 2011-09-07 |
DK1863767T3 (da) | 2009-05-04 |
NO20074622L (no) | 2007-10-18 |
CA2602445A1 (en) | 2006-09-28 |
CA2602445C (en) | 2013-08-20 |
ZA200708029B (en) | 2008-11-26 |
AU2006226665A1 (en) | 2006-09-28 |
ATE425144T1 (de) | 2009-03-15 |
CN101146775B (zh) | 2012-07-18 |
IL185689A (en) | 2012-05-31 |
AU2006226665B2 (en) | 2011-01-27 |
PT1863767E (pt) | 2009-03-27 |
RU2007134901A (ru) | 2009-04-27 |
BRPI0609699A2 (pt) | 2010-04-20 |
EP1863767B1 (en) | 2009-03-11 |
TW200700390A (en) | 2007-01-01 |
DE602006005624D1 (de) | 2009-04-23 |
ES2320590T3 (es) | 2009-05-25 |
RU2404969C2 (ru) | 2010-11-27 |
US7211579B2 (en) | 2007-05-01 |
EP1863767A1 (en) | 2007-12-12 |
KR100903224B1 (ko) | 2009-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200803811B (en) | Neuropolin antagonists | |
EP1997270A4 (en) | DIGIPASS FOR WEB FUNCTIONAL DESCRIPTION | |
GB0502418D0 (en) | Compounds | |
HK1123038A1 (en) | Heterocyclic compounds | |
GB0502316D0 (en) | Compounds | |
PL1863803T3 (pl) | Podstawione piperydyny | |
EP1961741A4 (en) | M-CARBAZOLYLPHENYL COMPOUNDS | |
AP2672A (en) | Glucuronidate nebivoloi metabolites | |
HK1121755A1 (en) | New compounds iii | |
GB0521275D0 (en) | 3-Aminoindole compounds | |
GB0502310D0 (en) | Compounds | |
IL185689A0 (en) | Metabolites for nk-i antagonists for emesis | |
EP1888082A4 (en) | MOTILIDVERBINDUNGEN | |
EP1907385A4 (en) | LINKS | |
IL177038A0 (en) | Methods for making 4-tetrazolyl-4-phenylpiperidine compounds | |
ZA200803017B (en) | Heterocyclic compounds | |
HU0500524D0 (en) | Equipment for energy-economical alcohol-distillatory | |
HU0400305D0 (en) | Set for spine-fixture | |
GB0501985D0 (en) | Compounds | |
EP1867650A4 (en) | HYDROXYMETHYLBORVERBINDUNGEN | |
GB0501984D0 (en) | Compounds | |
EP1904776A4 (en) | ARRANGEMENT OF TOOL EQUIPMENT | |
GB0511321D0 (en) | Inorganic compounds | |
TWM292850U (en) | Four-keys telephone set for emergent-call | |
GB0520137D0 (en) | Extending stand for plastering |